Journal of Experimental & Clinical Cancer Research最新文献

筛选
英文 中文
Correction: Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin. 更正:敲除 THOC1 可减少肝细胞癌的增殖并增加对顺铂的敏感性。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-14 DOI: 10.1186/s13046-024-03208-3
Shijiao Cai, Yunpeng Bai, Huan Wang, Zihan Zhao, Xiujuan Ding, Heng Zhang, Xiaoyun Zhang, Yantao Liu, Yan Jia, Yinan Li, Shuang Chen, Honggang Zhou, Huijuan Liu, Cheng Yang, Tao Sun
{"title":"Correction: Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.","authors":"Shijiao Cai, Yunpeng Bai, Huan Wang, Zihan Zhao, Xiujuan Ding, Heng Zhang, Xiaoyun Zhang, Yantao Liu, Yan Jia, Yinan Li, Shuang Chen, Honggang Zhou, Huijuan Liu, Cheng Yang, Tao Sun","doi":"10.1186/s13046-024-03208-3","DOIUrl":"https://doi.org/10.1186/s13046-024-03208-3","url":null,"abstract":"","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"285"},"PeriodicalIF":11.4,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472587/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142485897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer. 神经浸润介导的肿瘤代谢重编程影响非小细胞肺癌免疫疗法疗效的机制。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-10 DOI: 10.1186/s13046-024-03202-9
Yuanyuan Zheng, Lifeng Li, Zhibo Shen, Longhao Wang, Xiaoyu Niu, Yujie Wei, Shilong Sun, Jie Zhao
{"title":"Mechanisms of neural infiltration-mediated tumor metabolic reprogramming impacting immunotherapy efficacy in non-small cell lung cancer.","authors":"Yuanyuan Zheng, Lifeng Li, Zhibo Shen, Longhao Wang, Xiaoyu Niu, Yujie Wei, Shilong Sun, Jie Zhao","doi":"10.1186/s13046-024-03202-9","DOIUrl":"10.1186/s13046-024-03202-9","url":null,"abstract":"<p><strong>Background: </strong>Current evidence underlines the active role of neural infiltration and axonogenesis within the tumor microenvironment (TME), with implications for tumor progression. Infiltrating nerves stimulate tumor growth and dissemination by secreting neurotransmitters, whereas tumor cells influence nerve growth and differentiation through complex interactions, promoting tumor progression. However, the role of neural infiltration in the progression of non-small cell lung cancer (NSCLC) remains unclear.</p><p><strong>Methods: </strong>This study employs the techniques of immunohistochemistry, immunofluorescence, RNA sequencing, molecular biology experiments, and a murine orthotopic lung cancer model to deeply analyze the specific mechanisms behind the differential efficacy of NSCLC immunotherapy from the perspectives of neuro-tumor signal transduction, tumor metabolism, and tumor immunity.</p><p><strong>Results: </strong>This study demonstrates that nerve growth factor (NGF) drives neural infiltration in NSCLC, and 5-hydroxytryptamine (5-HT), which is secreted by nerves, is significantly elevated in tumors with extensive neural infiltration. Transcriptome sequencing revealed that 5-HT enhanced glycolysis in NSCLC cells. Pathway analysis indicated that 5-HT activated the PI3K/Akt/mTOR pathway, promoting tumor metabolic reprogramming. This reprogramming exacerbated immunosuppression in the TME. Neutralizing 5-HT-mediated metabolic reprogramming in tumor immunity enhanced the efficacy of PD-1 monoclonal antibody treatment in mice.</p><p><strong>Conclusions: </strong>The findings of this study provide a novel perspective on the crosstalk between nerves and lung cancer cells and provide insights into further investigations into the role of nerve infiltration in NSCLC progression.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"284"},"PeriodicalIF":11.4,"publicationDate":"2024-10-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11465581/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394855","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors. 增强子循环蛋白 LDB1 通过与主转录因子合作调节体外 T-ALL 细胞系中 MYB 的表达。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-09 DOI: 10.1186/s13046-024-03199-1
Yan Li, Zimu Zhang, Juanjuan Yu, Hongli Yin, Xinran Chu, Haibo Cao, Yanfang Tao, Yongping Zhang, Zhiheng Li, Shuiyan Wu, Yizhou Hu, Frank Zhu, Jizhao Gao, Xiaodong Wang, Bi Zhou, Wanyan Jiao, Yumeng Wu, Yang Yang, Yanling Chen, Ran Zhuo, Ying Yang, Fenli Zhang, Lei Shi, Yixin Hu, Jian Pan, Shaoyan Hu
{"title":"Enhancer looping protein LDB1 modulates MYB expression in T-ALL cell lines in vitro by cooperating with master transcription factors.","authors":"Yan Li, Zimu Zhang, Juanjuan Yu, Hongli Yin, Xinran Chu, Haibo Cao, Yanfang Tao, Yongping Zhang, Zhiheng Li, Shuiyan Wu, Yizhou Hu, Frank Zhu, Jizhao Gao, Xiaodong Wang, Bi Zhou, Wanyan Jiao, Yumeng Wu, Yang Yang, Yanling Chen, Ran Zhuo, Ying Yang, Fenli Zhang, Lei Shi, Yixin Hu, Jian Pan, Shaoyan Hu","doi":"10.1186/s13046-024-03199-1","DOIUrl":"10.1186/s13046-024-03199-1","url":null,"abstract":"<p><strong>Background: </strong>Despite significant progress in the prognosis of pediatric T-cell acute lymphoblastic leukemia (T-ALL) in recent decades, a notable portion of children still confronts challenges such as treatment resistance and recurrence, leading to limited options and a poor prognosis. LIM domain-binding protein 1 (LDB1) has been confirmed to exert a crucial role in various physiological and pathological processes. In our research, we aim to elucidate the underlying function and mechanisms of LDB1 within the background of T-ALL.</p><p><strong>Methods: </strong>Employing short hairpin RNA (shRNA) techniques, we delineated the functional impact of LDB1 in T-ALL cell lines. Through the application of RNA-Seq, CUT&Tag, and immunoprecipitation assays, we scrutinized master transcription factors cooperating with LDB1 and identified downstream targets under LDB1 regulation.</p><p><strong>Results: </strong>LDB1 emerges as a critical transcription factor co-activator in cell lines derived from T-ALL. It primarily collaborates with master transcription factors (ERG, ETV6, IRF1) to cooperatively regulate the transcription of downstream target genes. Both in vitro and in vivo experiments affirm the essential fuction of LDB1 in the proliferation and survival of cell lines derived from T-ALL, with MYB identified as a significant downstream target of LDB1.</p><p><strong>Conclusions: </strong>To sum up, our research establishes the pivotal fuction of LDB1 in the tumorigenesis and progression of T-ALL cell lines. Mechanistic insights reveal that LDB1 cooperates with ERG, ETV6, and IRF1 to modulate the expression of downstream effector genes. Furthermore, LDB1 controls MYB through remote enhancer modulation, providing valuable mechanistic insights into its involvement in the progression of T-ALL.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"283"},"PeriodicalIF":11.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462673/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394852","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment. 高度转移性结直肠癌细胞的外泌体 miR-106a-5p 通过诱导肿瘤微环境中的巨噬细胞 M2 极化来驱动肝转移。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-09 DOI: 10.1186/s13046-024-03204-7
Yahang Liang, Junyu Li, Yuli Yuan, Houqiong Ju, Hualin Liao, Mingming Li, Yang Liu, Yao Yao, Lingling Yang, Taiyuan Li, Xiong Lei
{"title":"Exosomal miR-106a-5p from highly metastatic colorectal cancer cells drives liver metastasis by inducing macrophage M2 polarization in the tumor microenvironment.","authors":"Yahang Liang, Junyu Li, Yuli Yuan, Houqiong Ju, Hualin Liao, Mingming Li, Yang Liu, Yao Yao, Lingling Yang, Taiyuan Li, Xiong Lei","doi":"10.1186/s13046-024-03204-7","DOIUrl":"10.1186/s13046-024-03204-7","url":null,"abstract":"<p><strong>Background: </strong>The tumor microenvironment (TME) is a dynamic system orchestrated by intricate cell-to-cell crosstalk. Specifically, macrophages within the TME play a crucial role in driving tumor progression. Exosomes are key mediators of communication between tumor cells and the TME. However, the mechanisms underlying exosome-driven crosstalk between tumor cells and macrophages during colorectal cancer (CRC) progression remain incompletely elucidated.</p><p><strong>Methods: </strong>Single-cell RNA sequencing were analyzed using the Seurat package. Exosomes were isolated using ultracentrifugation and characterized by transmission electron microscopy, nanoparticle tracking analysis, and western blot. miRNAs differentially expressed in exosomes were analyzed using the limma package. CD206 expression in CRC tissues, exosomes tracing, and exosomal miR-106a-5p transport were observed through immunofluorescence. Macrophage polarization was assessed via qRT-PCR, ELISA, and flow cytometry. The interactions between miR-106a-5p, hnRNPA1, and SOCS6 were evaluated using miRNA pull-down, RIP, and dual-luciferase reporter assays. Transwell assays and liver metastasis model explored the role of exosomal miR-106a-5p-induced M2 macrophages in promoting CRC liver metastasis.</p><p><strong>Result: </strong>The proportion of M2 macrophages is increased in CRC with liver metastasis compared to those without. Highly metastatic CRC cells release exosomes enriched with miR-106a-5p, which promote macrophages M2 polarization by suppressing SOCS6 and activating JAK2/STAT3 pathway. These M2 macrophages reciprocally enhance CRC liver metastasis. hnRNPA1 regulate the transport of miR-106a-5p into exosomes. Clinically, elevated miR-106a-5p in plasma exosomes correlated with liver metastasis and poor prognosis.</p><p><strong>Conclusion: </strong>CRC-derived exosomal miR-106a-5p plays a critical role in promoting liver metastasis and is a potential biomarker for the prevention and treatment of CRC liver metastasis.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"281"},"PeriodicalIF":11.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462797/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Hepatocyte-derived Igκ promotes HCC progression by stabilizing electron transfer flavoprotein subunit α to facilitate fatty acid β-oxidation. 肝细胞衍生的Igκ通过稳定电子传递黄蛋白亚基α促进脂肪酸β氧化,从而促进肝癌的进展。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-09 DOI: 10.1186/s13046-024-03203-8
Jingjing Guo, Huining Gu, Sha Yin, Jiongming Yang, Qianqian Wang, Weiyan Xu, Yifan Wang, Shenghua Zhang, Xiaofeng Liu, Xunde Xian, Xiaoyan Qiu, Jing Huang
{"title":"Hepatocyte-derived Igκ promotes HCC progression by stabilizing electron transfer flavoprotein subunit α to facilitate fatty acid β-oxidation.","authors":"Jingjing Guo, Huining Gu, Sha Yin, Jiongming Yang, Qianqian Wang, Weiyan Xu, Yifan Wang, Shenghua Zhang, Xiaofeng Liu, Xunde Xian, Xiaoyan Qiu, Jing Huang","doi":"10.1186/s13046-024-03203-8","DOIUrl":"10.1186/s13046-024-03203-8","url":null,"abstract":"<p><strong>Background: </strong>Lipid metabolism dysregulation is a key characteristic of hepatocellular carcinoma (HCC) onset and progression. Elevated expression of immunoglobulin (Ig), especially the Igκ free light chain with a unique Vκ4-1/Jκ3 rearrangement in cancer cells, is linked to increased malignancy and has been implicated in colon cancer tumorigenesis. However, the role of Igκ in HCC carcinogenesis remains unclear. The aim of this study was to elucidate the pivotal roles of hepatocyte-derived Igκ in HCC development.</p><p><strong>Methods: </strong>The rearrangement sequence and expression level of hepatocyte-derived Igκ in HCC cells were determined via RT-PCR, Sanger sequencing, immunohistochemistry, and western blot analysis. The function of Igκ in HCC tumorigenesis was assessed by silencing Igκ using siRNA or gRNA in various HCC cell lines. To assess the role of Igκ in HCC pathogenesis in vivo, a mouse model with hepatocyte-specific Igκ knockout and diethylnitrosamine (DEN) and carbon tetrachloride (CCL4)-induced HCC was utilized. The molecular mechanism by which Igκ affects HCC tumorigenesis was investigated through multiomics analyses, quantitative real-time PCR, immunoprecipitation, mass spectrometry, immunofluorescence, and metabolite detection.</p><p><strong>Results: </strong>We confirmed that Igκ, especially Vκ4-1/Jκ3-Igκ, is highly expressed in human HCC cells. Igκ depletion inhibited HCC cell proliferation and migration in vitro, and hepatocyte-specific Igκ deficiency ameliorated HCC progression in mice with DEN and CCL4-induced HCC in vivo. Mechanistically, Vκ4-1/Jκ3-Igκ interacts with electron transfer flavoprotein subunit α (ETFA), delaying its protein degradation. Loss of Igκ led to a decrease in the expression of mitochondrial respiratory chain complexes III and IV, resulting in aberrant fatty acid β-oxidation (FAO) and lipid accumulation, which in turn inhibited HCC cell proliferation and migration.</p><p><strong>Conclusion: </strong>Our findings indicate that the Igκ/ETFA axis deregulates fatty acid β-oxidation, contributing to HCC progression, which suggests that targeting fatty acid metabolism may be an effective HCC treatment strategy. The results of this study suggest that hepatocyte-derived Vκ4-1/Jκ3-Igκ may serve as a promising therapeutic target for HCC.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"280"},"PeriodicalIF":11.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11462706/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Plasma-derived extracellular vesicles miR-335-5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma. 血浆源性细胞外囊泡 miR-335-5p 作为融合阳性横纹肌肉瘤的潜在诊断生物标记物
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-09 DOI: 10.1186/s13046-024-03197-3
Virginia Di Paolo, Alessandro Paolini, Angela Galardi, Patrizia Gasparini, Loris De Cecco, Marta Colletti, Silvia Lampis, Salvatore Raieli, Cristiano De Stefanis, Evelina Miele, Ida Russo, Valentina Di Ruscio, Michela Casanova, Rita Alaggio, Andrea Masotti, Giuseppe Maria Milano, Franco Locatelli, Angela Di Giannatale
{"title":"Plasma-derived extracellular vesicles miR-335-5p as potential diagnostic biomarkers for fusion-positive rhabdomyosarcoma.","authors":"Virginia Di Paolo, Alessandro Paolini, Angela Galardi, Patrizia Gasparini, Loris De Cecco, Marta Colletti, Silvia Lampis, Salvatore Raieli, Cristiano De Stefanis, Evelina Miele, Ida Russo, Valentina Di Ruscio, Michela Casanova, Rita Alaggio, Andrea Masotti, Giuseppe Maria Milano, Franco Locatelli, Angela Di Giannatale","doi":"10.1186/s13046-024-03197-3","DOIUrl":"10.1186/s13046-024-03197-3","url":null,"abstract":"<p><strong>Background: </strong>Rhabdomyosarcoma (RMS) is the most common pediatric soft tissue sarcoma, with embryonal (ERMS) and alveolar (ARMS) representing the two most common histological subtypes. ARMS shows poor prognosis, being often metastatic at diagnosis. Thus, the discovery of novel biomarkers predictive of tumor aggressiveness represents one of the most important challenges to overcome and may help the development of tailored therapies. In the last years, miRNAs carried in extracellular vesicles (EVs), small vesicles of endocytic origin, have emerged as ideal candidate biomarkers due to their stability in plasma and their tissue specificity.</p><p><strong>Methods: </strong>EVs miRNAs were isolated from plasma of 21 patients affected by RMS and 13 healthy childrens (HC). We performed a miRNA profile using the Serum/Plasma Focus microRNA PCR panels (Qiagen), and RT-qPCR for validation analysis. Statistically significant (p < 0.05) miRNAs were obtained by ANOVA test.</p><p><strong>Results: </strong>We identified nine EVs miRNAs (miR-483-5p, miR-132-3p, miR-766-3p, miR-454-3p miR-197-3p, miR-335-3p, miR-17-5p, miR-486-5p and miR-484) highly upregulated in RMS patients compared to HCs. Interestingly, 4 miRNAs (miR-335-5p, miR-17-5p, miR-486-5p and miR-484) were significantly upregulated in ARMS samples compared to ERMS. In the validation analysis performed in a larger group of patients only three miRNAs (miR-483-5p, miR-335-5p and miR-484) were differentially significantly expressed in RMS patients compared to HC. Among these, mir-335-5p was significant also when compared ARMS to ERMS patients. MiR-335-5p was upregulated in RMS tumor tissues respect to normal tissues (p = 0.00202) and upregulated significantly between ARMS and ERMS (p = 0.04). Furthermore, the miRNA expression correlated with the Intergroup Rhabdomyosarcoma Study (IRS) grouping system, (p = 0.0234), and survival (OS, p = 0.044; PFS, p = 0.025). By performing in situ hybridization, we observed that miR-335-5p signal was exclusively in the cytoplasm of cancer cells.</p><p><strong>Conclusion: </strong>We identified miR-335-5p as significantly upregulated in plasma derived EVs and tumor tissue of patients affected by ARMS. Its expression correlates to stage and survival in patients. Future studies are needed to validate miR-335-5p as prognostic biomarker and to deeply elucidate its biological role.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"282"},"PeriodicalIF":11.4,"publicationDate":"2024-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11463097/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394856","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction: STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A. 更正:STUB1 介导的 K63 链接泛素化 UHRF1 通过维持 PLA2G2A 的 DNA 高甲基化促进胆管癌的进展。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-08 DOI: 10.1186/s13046-024-03198-2
Junsheng Chen, Da Wang, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang, Yongjun Chen
{"title":"Correction: STUB1-mediated K63-linked ubiquitination of UHRF1 promotes the progression of cholangiocarcinoma by maintaining DNA hypermethylation of PLA2G2A.","authors":"Junsheng Chen, Da Wang, Guanhua Wu, Fei Xiong, Wenzheng Liu, Qi Wang, Yiyang Kuai, Wenhua Huang, Yongqiang Qi, Bing Wang, Yongjun Chen","doi":"10.1186/s13046-024-03198-2","DOIUrl":"https://doi.org/10.1186/s13046-024-03198-2","url":null,"abstract":"","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"279"},"PeriodicalIF":11.4,"publicationDate":"2024-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11460208/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142394851","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction. NAT10/ac4C/JunB通过驱动糖酵解成瘾促进TNBC恶性进展和免疫抑制。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-04 DOI: 10.1186/s13046-024-03200-x
Guozheng Li, Xin Ma, Shiyao Sui, Yihai Chen, Hui Li, Lei Liu, Xin Zhang, Lei Zhang, Yi Hao, Zihan Yang, Shuai Yang, Xu He, Qin Wang, Weiyang Tao, Shouping Xu
{"title":"NAT10/ac4C/JunB facilitates TNBC malignant progression and immunosuppression by driving glycolysis addiction.","authors":"Guozheng Li, Xin Ma, Shiyao Sui, Yihai Chen, Hui Li, Lei Liu, Xin Zhang, Lei Zhang, Yi Hao, Zihan Yang, Shuai Yang, Xu He, Qin Wang, Weiyang Tao, Shouping Xu","doi":"10.1186/s13046-024-03200-x","DOIUrl":"10.1186/s13046-024-03200-x","url":null,"abstract":"<p><strong>Background: </strong>N4-Acetylcytidine (ac4C), a highly conserved post-transcriptional mechanism, plays a pivotal role in RNA modification and tumor progression. However, the molecular mechanism by which ac4C modification mediates tumor immunosuppression remains elusive in triple-negative breast cancer (TNBC).</p><p><strong>Methods: </strong>NAT10 expression was analyzed in TNBC samples in the level of mRNA and protein, and compared with the corresponding normal tissues. ac4C modification levels also measured in the TNBC samples. The effects of NAT10 on immune microenvironment and tumor metabolism were investigated. NAT10-mediated ac4C and its downstream regulatory mechanisms were determined in vitro and in vivo. The combination therapy of targeting NAT10 in TNBC was further explored.</p><p><strong>Results: </strong>The results revealed that the loss of NAT10 inhibited TNBC development and promoted T cell activation. Mechanistically, NAT10 upregulated JunB expression by increasing ac4C modification levels on its mRNA. Moreover, JunB further up-regulated LDHA expression and facilitated glycolysis. By deeply digging, remodelin, a NAT10 inhibitor, elevated the surface expression of CTLA-4 on T cells. The combination of remodelin and CTLA-4 mAb can further activate T cells and inhibite tumor progression.</p><p><strong>Conclusion: </strong>Taken together, our study demonstrated that the NAT10-ac4C-JunB-LDHA pathway increases glycolysis levels and creates an immunosuppressive tumor microenvironment (TME). Consequently, targeting this pathway may assist in the identification of novel therapeutic strategies to improve the efficacy of cancer immunotherapy.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"278"},"PeriodicalIF":11.4,"publicationDate":"2024-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11451012/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142373422","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment. CALB2通过肿瘤微环境的炎症重编程驱动胰腺癌转移。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-03 DOI: 10.1186/s13046-024-03201-w
Jinxin Tao, Yani Gu, Zeyu Zhang, Guihu Weng, Yueze Liu, Jie Ren, Yanan Shi, Jiangdong Qiu, Yuanyang Wang, Dan Su, Ruobing Wang, Yifan Fu, Tao Liu, Liyuan Ye, Wenhao Luo, Hao Chen, Gang Yang, Zhe Cao, Hua Huang, Jianchun Xiao, Bo Ren, Lei You, Taiping Zhang, Yupei Zhao
{"title":"CALB2 drives pancreatic cancer metastasis through inflammatory reprogramming of the tumor microenvironment.","authors":"Jinxin Tao, Yani Gu, Zeyu Zhang, Guihu Weng, Yueze Liu, Jie Ren, Yanan Shi, Jiangdong Qiu, Yuanyang Wang, Dan Su, Ruobing Wang, Yifan Fu, Tao Liu, Liyuan Ye, Wenhao Luo, Hao Chen, Gang Yang, Zhe Cao, Hua Huang, Jianchun Xiao, Bo Ren, Lei You, Taiping Zhang, Yupei Zhao","doi":"10.1186/s13046-024-03201-w","DOIUrl":"10.1186/s13046-024-03201-w","url":null,"abstract":"<p><strong>Background: </strong>Early dissemination to distant organs accounts for the dismal prognosis of patients with pancreatic ductal adenocarcinoma (PDAC). Chronic, dysregulated, persistent and unresolved inflammation provides a preferred tumor microenvironment (TME) for tumorigenesis, development, and metastasis. A better understanding of the key regulators that maintain inflammatory TME and the development of predictive biomarkers to identify patients who are most likely to benefit from specific inflammatory-targeted therapies is crucial for advancing personalized cancer treatment.</p><p><strong>Methods: </strong>This study identified cell-specific expression of CALB2 in human PDAC through single-cell RNA sequencing analysis and assessed its clinicopathological correlations in tissue microarray using multi-color immunofluorescence. Co-culture systems containing cancer-associated fibroblasts (CAFs) and patient-derived organoids (PDOs) in vitro and in vivo were employed to elucidate the effects of CALB2-activated CAFs on PDAC malignancy. Furthermore, CUT&RUN assays, luciferase reporter assays, RNA sequencing, and gain- or loss-of-function assays were used to unravel the molecular mechanisms of CALB2-mediated inflammatory reprogramming and metastasis. Additionally, immunocompetent KPC organoid allograft models were constructed to evaluate CALB2-induced immunosuppression and PDAC metastasis, as well as the efficacy of inflammation-targeted therapy.</p><p><strong>Results: </strong>CALB2 was highly expressed both in CAFs and cancer cells and correlated with an unfavorable prognosis and immunosuppressive TME in PDAC patients. CALB2 collaborated with hypoxia to activate an inflammatory fibroblast phenotype, which promoted PDAC cell migration and PDO growth in vitro and in vivo. In turn, CALB2-activated CAFs upregulated CALB2 expression in cancer cells through IL6-STAT3 signaling-mediated direct transcription. In cancer cells, CALB2 further activated Ca<sup>2+</sup>-CXCL14 inflammatory axis to facilitate PDAC metastatic outgrowth and immunosuppression. Genetic or pharmaceutical inhibition of CXCL14 significantly suppressed CALB2-mediated metastatic colonization of PDAC cells in vivo and extended mouse survival.</p><p><strong>Conclusions: </strong>These findings identify CALB2 as a key regulator of inflammatory reprogramming to promote PDAC metastatic progression. Combination therapy with αCXCL14 monoclonal antibody and gemcitabine emerges as a promising strategy to suppress distant metastasis and improve survival outcomes in PDAC with CALB2 overexpression.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"277"},"PeriodicalIF":11.4,"publicationDate":"2024-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11448066/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142367268","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas. IRF2 的缺失与大多数人类癌症亚群中 MHC I 通路转录物的减少有关,并导致人类和小鼠黑色素瘤对检查点免疫疗法产生抗药性。
IF 11.4 1区 医学
Journal of Experimental & Clinical Cancer Research Pub Date : 2024-10-02 DOI: 10.1186/s13046-024-03187-5
G Sari, K Dhatchinamoorthy, L Orellano-Ariza, L M Ferreira, M A Brehm, K Rock
{"title":"IRF2 loss is associated with reduced MHC I pathway transcripts in subsets of most human cancers and causes resistance to checkpoint immunotherapy in human and mouse melanomas.","authors":"G Sari, K Dhatchinamoorthy, L Orellano-Ariza, L M Ferreira, M A Brehm, K Rock","doi":"10.1186/s13046-024-03187-5","DOIUrl":"10.1186/s13046-024-03187-5","url":null,"abstract":"<p><strong>Background: </strong>In order for cancers to progress, they must evade elimination by CD8 T cells or other immune mechanisms. CD8 T cells recognize and kill tumor cells that display immunogenic tumor peptides bound to MHC I molecules. One of the ways that cancers can escape such killing is by reducing expression of MHC I molecules, and loss of MHC I is frequently observed in tumors. There are multiple different mechanisms that can underly the loss of MHC I complexes on tumor and it is currently unclear whether there are particular mechanisms that occur frequently and, if so, in what types of cancers. Also of importance to know is whether the loss of MHC I is reversible and how such loss and/or its restoration would impact responses to immunotherapy. Here, we investigate these issues for loss of IRF1 and IRF2, which are transcription factors that drive expression of MHC I pathway genes and some killing mechanisms.</p><p><strong>Methods: </strong>Bioinformatics analyses of IRF2 and IRF2-dependent gene transcripts were performed for all human cancers in the TCGA RNAseq database. IRF2 protein-DNA-binding was analyzed in ChIPseq databases. CRISRPcas9 was used to knock out IRF1 and IRF2 genes in human and mouse melanoma cells and the resulting phenotypes were analyzed in vitro and in vivo.</p><p><strong>Results: </strong>Transcriptomic analysis revealed that IRF2 expression was reduced in a substantial subset of cases in almost all types of human cancers. When this occurred there was a corresponding reduction in the expression of IRF2-regulated genes that were needed for CD8 T cell recognition. To test cause and effect for these IRF2 correlations and the consequences of IRF2 loss, we gene-edited IRF2 in a patient-derived melanoma and a mouse melanoma. The IRF2 gene-edited melanomas had reduced expression of transcripts for genes in the MHC I pathway and decreased levels of MHC I complexes on the cell surface. Levels of Caspase 7, an IRF2 target gene involved in CD8 T cell killing of tumors, were also reduced. This loss of IRF2 caused both human and mouse melanomas to become resistant to immunotherapy with a checkpoint inhibitor. Importantly, these effects were reversible. Stimulation of the IRF2-deficient melanomas with interferon induced the expression of a functionally homologous transcription factor, IRF1, which then restored the MHC I pathway and responsiveness to CPI.</p><p><strong>Conclusions: </strong>Our study shows that a subset of cases within most types of cancers downregulates IRF2 and that this can allow cancers to escape immune control. This can cause resistance to checkpoint blockade immunotherapy and is reversible with currently available biologics.</p>","PeriodicalId":50199,"journal":{"name":"Journal of Experimental & Clinical Cancer Research","volume":"43 1","pages":"276"},"PeriodicalIF":11.4,"publicationDate":"2024-10-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11446056/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142362436","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信